Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs, but there is concern that they may increase the risk of malignant neoplasia. The present meta-analysis examined the safety of GLP-1 receptor agonists with regard to malignant neoplasia. METHODS: We an...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yufang, Zhang, Xiaomei, Chai, Sanbao, Zhao, Xin, Ji, Linong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664552/
https://www.ncbi.nlm.nih.gov/pubmed/31396537
http://dx.doi.org/10.1155/2019/1534365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664552/
https://www.ncbi.nlm.nih.gov/pubmed/31396537
http://dx.doi.org/10.1155/2019/1534365

Ejemplares similares